Pregabalin CAS 148553-50-8 Ubunyulu > 99.0% (HPLC) Antiepileptic API
Umenzi onobunyulu obuPhezulu kunye neMveliso yoRhwebo
Igama leKhemikhali: PregabalinCAS: 148553-50-8
I-Pregabalin sisiyobisi se-antiepileptic sesizukulwana sesibini (AED)
Igama leMchiza | Pregabalin |
Izithethantonye | (S) -3-(Aminomethyl) -5-Methylhexanoic Acid;PD-144723;PD144723;CI 1008;I-CI-1008;Lyrica |
Inombolo yeCAS | 148553-50-8 |
Inombolo yeCAT | RF-API57 |
Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
Ifomula yeemolekyuli | C8H17NO2 |
Ubunzima beMolekyuli | 159.23 |
Indawo yokunyibilika | 194.0 ~ 196.0℃ |
Ukunyibilika emanzini | Ayinyibiliki ngokupheleleyo emanzini |
Ukunyibilika | Kancinci kakhulu ukunyibilika kwi-Ethanol |
Imeko yokuthumela ngenqanawa | Phantsi koBubushushu be-Ambient |
Uphawu | Ruifu Chemical |
Into | Iinkcukacha |
Imbonakalo | Mhlophe ukuya kuMhlophe oMhlophe wePowder |
Ukuchongwa | I-IR: Ifana neNgcaciso yeNgcaciso |
Ukujikeleziswa okuthe ngqo | +10.0°~+13.0° (C=1, Amanzi) |
Ilahleko ekomisweni | <0.50% |
Uthuthu lweSulfate | <0.10% |
Izinto ezinxulumeneyo | Ukungcola A <0.15% |
Ubumdaka obungachazwanga eluting phambi kwePregabalin (uvavanyo A) <0.10% | |
Ukungcola Okungachazwanga Eluting Emva kwe-Pregabalin (uvavanyo B ) <0.10% | |
Itotali yovavanyo A kunye B <0.50% | |
Ubunyulu Ngu-HPLC R-Isomer | <0.15% |
Iintsimbi ezinzima (njenge Pb) | <10ppm |
Iikloridi (Cl) | <0.05% |
Izinyibilikisi ezishiyekileyo | |
Isopropyl Utywala | <5000ppm |
I-Ethyl Acetate | <5000ppm |
Tetrahydrofuran | <250ppm |
I-Isopropyl Etere | <500ppm |
I-Ethanol | <1000ppm |
Ubunyulu / Indlela yokuHlalutya | >99.0% (HPLC ngokomisiweyo) |
Umgangatho woVavanyo | Umgangatho woShishino |
Ukusetyenziswa | Antiepileptic Drug API |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma
I-Pregabalin iyeza lesibini lesizukulwana sesibini se-antiepileptic (AED) eyaziwa ngegama lobunikazi be-Lyrica (Pfizer, Tadworth) e-UK nase-USA, ene-γ-amino butyric structure kwisakhiwo sayo se-molecular, esinemiphumo ye-anticonvulsant. iphuhliswe ngempumelelo yinkampani iPfizer kunyango lweentlungu ze-neuropathic zeperipheral, okanye unyango lwe-adjuvant lokubanjwa kancinci.I-Pregabalin sisiyobisi se-Anticonvulsant kunye ne-antiepileptic esetyenziselwa ukunyanga isifo sokuxhuzula, intlungu ye-neuropathic, i-fibromyalgia, kunye nokuphazamiseka kokuxhalabisa ngokubanzi.Ukusetyenziswa kwayo kwisifo sokuxhuzula njengonyango olongezelelekileyo lokuxhuzula ngokuyinxenye kunye okanye ngaphandle kokwenziwa ngokubanzi okwesibini kubantu abadala.NgoDisemba 2008, i-US Food and Drug Administration (FDA) ivume i-pregabalin (igama lorhwebo "Lyrica") kunyango lwe-diabetic peripheral neuropathic pain (DPN) kunye ne-postherpetic neuralgia (PHN) ezo zombini iintlungu eziqhelekileyo ze-neuropathic.I-Pregabalin inesalathiso esivunyiweyo kwaye isetyenziswa ngokubanzi kunyango lwengxaki yokukhathazeka ngokubanzi.Uvavanyo oluninzi olungahleliwe, oluyimfama oluphindwe kabini, olulawulwa yi-placebo lufumanise ukuba i-pregabalin lunyango olusebenzayo kwizigulana ezinoxinzelelo oluqhelekileyo loxinzelelo kunye nokuphazamiseka kwentlalo.I-dose titration Unyango lwe-Epilepsy-adjunctive: 25 mg bd kwiintsuku ze-7, inyuswe nge-50 mg rhoqo ngeentsuku ze-7;ukugcinwa okuqhelekileyo kwe-300 mg yonke imihla, yahlulwe kwi-2 okanye i-3 iidosi (max. 600 mg yonke imihla, yahlulahlulwe kwi-2 okanye i-3 doses).Ingxaki yokukhathazeka ngokubanzi: I-150 mg imihla ngemihla, ihlulwe kwi-2 okanye i-3 doses, kwiintsuku ze-7, inyuswe nge-150 mg yonke imihla ye-7 (max. 600 mg imihla ngemihla, ihlulwe kwi-2 okanye i-3 doses).Ukuba uyeka i-pregabalin, kuyacetyiswa ukuba ucofe ngaphezulu kweveki enye ukunqanda ukurhoxa ngokukhawuleza.Izilumkiso Izigulana ezineemeko ezinokuthi zibangele i-encephalopathy.Izigulane ezineentliziyo ezinzima ezixinzelelekileyo.